Xeolas Pharmaceuticals Limited

Quick facts

Phase 3 pipeline

• Soludronate® · Bone metabolism / Osteoporosis
  Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Xeolas Pharmaceuticals Limited portfolio CI brief
• Xeolas Pharmaceuticals Limited pipeline updates RSS